Since the inhibition of NTCP is a pharmacological target in the treatment of hepatitis B and D viruses infections, hepatic fibrosis, and hepatosteatosis (40), monitoring the levels of total BAs and vitamin D and the bone density should also be considered during NTCP inhibitor development. This evidence concerns the gene SLC10A1 and Hepatic fibrosis.